Today 4D Pharma has released encouraging preliminary safety and clinical observation data from its Phase I/II study of MRx0518 in combination with Keytruda® in patients with advanced and progressive malignancies. Initial data shows the therapy combination was well-tolerated producing no drug-related serious adverse events, and that early clinical observations show that two patients demonstrated a partial response and a third patient presented stable disease - a significant feature given the adva ....